Laboratory Considerations for Clinical Trials

In this episode, Dr. Wayne Hogrefe and Dr. Pat Hurban discuss the use of NGS in the development and assessment of new vaccines against the influenza virus.

Topics covered include:

• What health organizations are looking for that drives the selection of the next season's vaccine strains
• How sequence data is used to evaluate the effectiveness of a vaccine while providing insight into the evolution of the virus
• How the sequence data can inform the development of new types of vaccines and therapeutics
• The prospects for a vaccine that is effective across multiple strains and multiple seasons
• How NGS data differs from traditional Sanger sequencing data and what can be learned from that

You can learn more about this topic at www.q2labsolutions.com